Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

ClinicalTrials.gov ID: NCT05747924

Public ClinicalTrials.gov record NCT05747924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study identification

NCT ID: NCT05747924
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Avidity Biosciences, Inc.; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Interventions

AOC 1020 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 16 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 3, 2023
Primary completion: Mar 17, 2026
Completion: Mar 19, 2026
Last update posted: Jul 15, 2026

2023 – 2026

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of California Los Angeles	Los Angeles	California	90095	—
Stanford University	Palo Alto	California	94304	—
University of California San Diego	San Diego	California	92093	—
University of Colorado	Denver	Colorado	80045	—
University of Florida	Gainesville	Florida	32608	—
Rare Disease Research	Atlanta	Georgia	30329	—
Kansas University Medical Center	Kansas City	Kansas	66205	—
University of Rochester Medical Center	Rochester	New York	14642	—
Duke University	Durham	North Carolina	27708	—
Ohio State University	Columbus	Ohio	43221	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
University of Texas Southwestern	Dallas	Texas	75390	—
Virginia Commonwealth University	Richmond	Virginia	23298	—
University of Washington	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05747924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 15, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05747924 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →